Home Cart Sign in  
Chemical Structure| 1410880-22-6 Chemical Structure| 1410880-22-6

Structure of JNK-IN-8
CAS No.: 1410880-22-6

Chemical Structure| 1410880-22-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JNK-IN-8 is a potent JNK inhibitor with IC50 values of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.

Synonyms: JNK Inhibitor XVI; c-Jun N-terminal Kinase Inhibitor XVI

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JNK-IN-8

CAS No. :1410880-22-6
Formula : C29H29N7O2
M.W : 507.59
SMILES Code : O=C(NC1=CC=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C(C)=C1)C4=CC=CC(NC(C=CCN(C)C)=O)=C4
Synonyms :
JNK Inhibitor XVI; c-Jun N-terminal Kinase Inhibitor XVI
MDL No. :MFCD22124890
InChI Key :GJFCSAPFHAXMSF-UXBLZVDNSA-N
Pubchem ID :57340686

Safety of JNK-IN-8

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of JNK-IN-8

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK1

    JNK1, IC50:4.7 nM

  • JNK2

    JNK2, IC50:18.7 nM

  • JNK3

    JNK3, IC50:1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BV2 microglial cells 10 mM JNK-IN-8 treatment inhibited the activation of BV2 microglial cells and reduced the expression of TNF-α, IL-1β, and IL-6 PMC6916328
MDS-L cells 10 μM To investigate the inhibitory effect of JNK-IN-8 on WFA-induced C-JUN phosphorylation, results showed that JNK-IN-8 pretreatment inhibited WFA-induced C-JUN phosphorylation. PMC5652791
WPMY-1 cells 2 μM 48 h Inhibition of c-JUN phosphorylation, mimicking the effect of lactate on p62 expression. PMC9136538
Normal human mammary epithelial cells 2μM 24 h To test the effect of the JNK inhibitor on apoptosis of mammary epithelial cells in suspension culture, results showed that the JNK inhibitor strongly suppressed apoptosis induced by suspension culture. PMC5711519
PC-3 cells 1 μM and 2 μM JNK-IN-8 counteracted the reduction in phosphorylation levels of JNK and C-Jun, induced by ASPA knockdown, in a dose-dependent manner PMC10240701
SKMEL2 cells 200 nM 48 h To study the effect of JNK-IN-8 on AP-1 activity, results showed that JNK-IN-8 suppressed AP-1 activity in NT cells but failed to rescue AP-1 activation in GRAMD1B knockdown cells. PMC9827116
H1 hESCs 1 μM 1 day JNK inhibitor treatment significantly improved DE differentiation efficiency and reduced differentiation variability PMC6545159
HUES8 hESCs 1 μM 1 day JNK inhibitor treatment significantly improved DE differentiation efficiency and reduced differentiation variability PMC6545159
HUES6 hESCs 1 μM 1 day JNK inhibitor treatment significantly improved DE differentiation efficiency and reduced differentiation variability PMC6545159
BJ hiPSCs 1 μM 1 day JNK inhibitor treatment significantly improved DE differentiation efficiency and reduced differentiation variability PMC6545159
CV hiPSCs 1 μM 1 day JNK inhibitor treatment significantly improved DE differentiation efficiency and reduced differentiation variability PMC6545159

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NF2 LOF mutants-induced IOMM-Lee xenograft tumor model Intraperitoneal injection 10 mg/kg Every other day for 15 days JNK-IN-8 significantly attenuated the NF2 LOF mutants-induced IOMM-Lee xenograft tumor growth PMC11582751
Rats Transient middle cerebral artery occlusion (tMCAO) model Intraperitoneal injection 20 mg/kg Single dose, 2 hours after MCAO JNK-IN-8 treatment significantly improved neurological functional recovery in MCAO rats, inhibited microglial activation and JNK/NF-κB signaling pathway, and reduced the production of pro-inflammatory cytokines PMC6916328
mice SUM149 xenograft model intraperitoneal injection 15 mg/kg and 30 mg/kg daily for 34 days JNK-IN-8 significantly suppressed tumor growth and reduced CSC phenotype PMC6116358

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.85mL

1.97mL

0.99mL

19.70mL

3.94mL

1.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories